Genedrive Expands Stroke Test Use at Southmead Hospital with Charity Funding

Genedrive plc (LSE:GDR) has confirmed that its CYP2C19 ID Kit will be introduced at North Bristol NHS Trust’s Southmead Hospital, specifically within its Hyperacute and Acute Stroke Units. The rollout is supported by £80,000 in funding from the Medlock Charitable Trust, chaired by major shareholder David Medlock. The initiative is expected to benefit around 1,500 stroke patients treated at the hospital each year by helping clinicians quickly determine which individuals may not respond effectively to clopidogrel, a commonly prescribed antiplatelet drug.

The funding will be administered through Southmead Hospital Charity, which enables enhancements to patient care beyond standard NHS resources. Meanwhile, the hospital’s stroke team is preparing a proposal to secure longer-term funding through the local Integrated Care Board once the initial programme concludes. Leaders from Genedrive, the Medlock Charitable Trust, and Bristol’s NHS services подчеркнули that the collaboration brings advanced point-of-care genetic testing into stroke aftercare, with the goal of tailoring treatment decisions, improving patient outcomes, and potentially lowering overall healthcare costs. The move also reinforces Genedrive’s role in advancing precision medicine within NHS pathways.

From a financial standpoint, the company continues to face challenges, including persistent losses, ongoing cash outflows, and a declining equity base, albeit with limited debt exposure. Market indicators suggest some near-term strength, with the share price trading above key averages and a positive MACD reading, though a high RSI points to possible short-term overextension. Valuation remains difficult to justify given negative earnings and the absence of a meaningful price-to-earnings ratio.

More about Genedrive

Genedrive plc is a UK-based diagnostics company focused on pharmacogenetic testing solutions designed for rapid use at the point of care. Its products aim to support safer and more effective prescribing in acute and emergency settings. Key offerings include the CYP2C19 ID Kit, used to guide antiplatelet therapy in stroke patients, and the MT-RNR1 ID Kit, which helps prevent antibiotic-related hearing loss in newborns. The company is working to integrate precision diagnostics into routine NHS practice while also pursuing opportunities for international expansion.